Hostname: page-component-cd9895bd7-p9bg8 Total loading time: 0 Render date: 2024-12-28T01:51:23.445Z Has data issue: false hasContentIssue false
  • English
  • Français

Treatment of Heredo-Degenerative Ataxias with Amantadine Hydrochloride

Published online by Cambridge University Press:  18 September 2015

M.I. Botez ,
Simon N. Young ,
Thérèse Botez  and
Olga L. Pedraza
M.I. Botez
Affiliation:
Laboratory of Clinical Neuropsychology and Behavioral Neurology, Neurology Service, Hôtel-Dieu Hospital, Université de Montréal and the Department of Psychiatry, McGill University, Montréal
Simon N. Young
Affiliation:
Laboratory of Clinical Neuropsychology and Behavioral Neurology, Neurology Service, Hôtel-Dieu Hospital, Université de Montréal and the Department of Psychiatry, McGill University, Montréal
Thérèse Botez*
Affiliation:
Laboratory of Clinical Neuropsychology and Behavioral Neurology, Neurology Service, Hôtel-Dieu Hospital, Université de Montréal and the Department of Psychiatry, McGill University, Montréal
Olga L. Pedraza
Affiliation:
Laboratory of Clinical Neuropsychology and Behavioral Neurology, Neurology Service, Hôtel-Dieu Hospital, Université de Montréal and the Department of Psychiatry, McGill University, Montréal
*
Neurology Service, Hôtel-Dieu de Montréal, 3840 St-Urbain Street, Montréal, Québec, Canada H2W IT8
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Amantadine hydrochloride (AH) was administered (200 mg/day) for more than three months to 17 patients with Friedreich's ataxia (FA) and to 12 patients with olivopontocerebellar atrophies (OPCA) in an open clinical trial. Reaction time (RT) and movement time (MT) with the right and left hand were measured before and after treatment. A striking improvement on both RT and MT was observed in the OPCA group (on seven out of eight measures), whereas in the FA patients improvement was seen only in two out of four MT measures with no improvement in RT. Both groups had low levels of homovanillic acid (HVA) in their cerebrospinal fluid before treatment, relative to their controls. However, improvement with AH was not related to HVA levels.

Type
Original Articles
Information
Canadian Journal of Neurological Sciences , Volume 18 , Issue 3 , August 1991 , pp. 307 - 311
Copyright
Copyright © Canadian Neurological Sciences Federation 1991

References

REFERENCES

1.Botez, T, Botez, MI, Parent, C, et al. Etude pré1iminaire évaluant l’effet a court terme de léamantadine et du L-tryptophane associé au carbidopa dans le traitement des ataxies spinocérébelleuses. Medecine/sciences 1988; 46A: (Suppl. 1).Google Scholar
2.Botez, MI, Young, SN, Botez, T, et al. Treatment of Friedreich’s ataxia with amantadine. Neurology 1989; 39: 749–750 (letter).CrossRefGoogle ScholarPubMed
3.Von Voigtlander, P, Moore, K. Dopamine: release from the brain in vivo by amantadine. Science 1970; 174: 408–410.CrossRefGoogle Scholar
4.Petersen, PL, Saad, J, Nigra, MA. The treatment of Friedreich’s ataxia with amantadine hydrochloride. Neurology 1988; 38: 1478–1480.CrossRefGoogle Scholar
5.Noica, D, Draganesco, S. Sur un symptôme caractéristique d’une lésion des noyaux centraux moteurs: la rigidité musculaire latente. Rev Neurol 1935; 63: 75–79.Google Scholar
6.Botez, MI. Frontal lobe tumours. In: Vinken, PJ and Bruyn, GW, eds. Handbook of Clinical Neurology, Vol. 17, Part II, Amsterdam; North Holland 1974: 234–280.Google Scholar
7.Botez, MI, Attig, E, Vezina, JL. Cerebellar atrophy in epileptic patients. Can J Neurol Sci 1988; 15: 299–303.CrossRefGoogle ScholarPubMed
8.Smedley hand dynamometer. Manual. Catalog number 19117, Stoelting Company, Chicago (IL), 1972, 2 pp.Google Scholar
9.Harding, AE. The inherited ataxias. In: Di Donato, S, et al., eds. Advances in Neurology, Vol. 48: Molecular Genetics of Neurological and Neuromuscular Disease. New York; Raven Press 1988: 37–45.Google Scholar
10.Huang, YP, Plaitakis, A. Morphological changes of olivopontocerebellar atrophy in computed tomography and comments on its pathogenesis. In: Duvoisin, RC and Plaitakis, A, eds. The Olivopontocerebellar Atrophies. Advances in Neurology, New York, Raven Press 1984; 41: 39–86.Google Scholar
11.Hamsher, KS, Benton, AL. The reliability of reaction time determinations. Cortex 1977; 3: 306–310.CrossRefGoogle Scholar
12.Botez, MI, Young, SN. Effects of anticonvulsant treatment and low levels of folate and thiamine on amine metabolites in cerebrospinal fluid. Brain 1991; 114: 333–348.Google ScholarPubMed
13.Anderson, GM, Young, SN, Cohen, DJ. Rapid liquid chromatography determination of tryptophan, tyrosine, 5-hydroxyindoleacetic acid and homovanillic acid in cerebrospinal fluid. J Chromatogr 1979; 164: 501–505.CrossRefGoogle ScholarPubMed
14.Ichikawa, N. Study on monoamine metabolite contents of cerebrospinal fluid in patients with neurodegenerative diseases. Tohoku J Exp Med 1986; 150: 435–446.CrossRefGoogle Scholar
15.Polinsky, RJ, Brown, RT, Burns, RS, et al. Low lumbar CSF levels of homovanillic acid and 5-hydroxyindoleacetic acid in multiple system atrophy with autonomic failure. J. Neurol Neurosurg Psychiatry 1988; 51: 914–919.CrossRefGoogle ScholarPubMed
16.Botez, MI, Gravel, J, Attig, E, et al. Reversible chronic cerebellar ataxia after phenytoin intoxication: possible role of cerebellum in cognitive thought. Neurology 1985; 35: 1152–1157.CrossRefGoogle ScholarPubMed
17.Botez, MI, Botez, T, Elie, R, et al. Role of the cerebellum in complex human behavior. Ital J Neurol Sci 1989; 10: 291–300.CrossRefGoogle ScholarPubMed
18.Botez, T, Botez, MI, Cardu, B, et al. Speed of information processing and its relationship to intelligence at various levels of the central nervous system. Neurology 1989; 39: 318 (Suppl. 1) (abstract).Google Scholar
19.Botez, MI, Leveille, J, Botez, T. Role of the cerebellum in cognitive thought. In: Matheson, M and Newman, H, eds. Proceedings of the Thirteenth Annual Brain Impairment Conference, Australian Society for the Study of Brain Impairment, Sydney 1989: 179–195.Google Scholar
20.Benton, AL, Blackburn, HL. Practice effects in reaction time tasks in brain-injured patients. J Abn Soc Psychol 1957; 54: 109–113.CrossRefGoogle ScholarPubMed
21.Vernon, PA. Speed of information processing and general intelligence. Intelligence 1983; 7: 53–70.CrossRefGoogle Scholar
22.Ladurner, G, Tschinkel, M, Klebb, H, et al. Reaction time in cerebrovascular disease. Arch Gerontol Geriat 1985: 4: 373–379.CrossRefGoogle ScholarPubMed
23.Baker, SJ, Maurissen, JP, Chrzan, GJ. Simple reaction time and movement time in human volunteers. Percept Motor Skills 1986; 63: 767–774.CrossRefGoogle Scholar
24.Jensen, AR, Munro, E. Reaction time, movement time and intelligence. Intelligence 1979; 3: 121–126.CrossRefGoogle Scholar
25.Vernon, PA. Reaction time and intelligence in the mentally retarded. Intelligence 1981; 5: 345–355.CrossRefGoogle Scholar
26.Botez, MI, Gravel, J, Ross-Chouinard, A, et al. Folate and thiamine treatment in epileptic patients. Neurology 1987; 37: 349 (Suppl. 1) (abstract).Google Scholar
27.Schut, JW, Haymaker, W. Hereditary ataxia: Pathological study of 5 cases of common ancestry. J Neuropathol Clin Neurol 1951; 1: 183–213.Google Scholar
28.Caplan, LR. Clinical features of sporadic (Dejerine-Thomas) olivopontocerebellar atrophy. In: Duvoisin, RC and Plaitakis, A, eds. The Olivopontocerebellar Atrophies. Advances in Neurology, Vol. 41, New York; Raven Press 1984: 217–224.Google Scholar
29.Goetz, CG, Tanner, CM, Klawans, HL. The pharmacology of olivopontocerebellar atrophy. In: Duvoisin, RC and Plaitakis, A, eds. The Olivopontocerebellar Atrophies. Advances in Neurology, New York; Raven Press 1984; 41: 143–148.Google ScholarPubMed
30.Wadia, NH. A variety of olivopontocerebellar atrophy distinguished by slow eye movements and peripheral neuropathy. In: Duvoisin, RC and Plaitakis, A, eds. The Olivopontocerebellar Atrophies. Advances in Neurology, New York; Raven Press 1984; 41: 149–177.Google ScholarPubMed
31.Bak, L, Hassler, R, Kim, J, et al. Amantadine actions on acetylcholine and GABA in striatum and substantia nigra of rat in relation to behavioral changes. J Neurol Transm 1972; 33: 4561.CrossRefGoogle ScholarPubMed
32.Bonnet, AM, Esteguy, M, Tell, G, et al. A controlled study of oral Vigabatrin (gamma-vinyl GABA) in patients with cerebellar ataxia. Can J Neurol Sci 1986; 13: 331–333.CrossRefGoogle ScholarPubMed
33.Pentland, B, Martyn, CN, Steer, RC, et al. Lecithin treatment in Friedreich’s ataxia. Br Med J 1981; 282: 1197.CrossRefGoogle ScholarPubMed
34.Snider, RA, Maiti, A, Snider, SR. Cerebellar pathways to ventral midbrain and nigra. Exp Neurol 1976; 53: 714–728.CrossRefGoogle ScholarPubMed
35.Amalric, M, Koob, GF. Depletion of dopamine in the caudate nucleus but not in nucleus accumbens impairs reaction-time performance in rats. J Neurosci 1987; 7: 2129–2134.CrossRefGoogle Scholar
36.Sawaguchi, T. Catecholamine sensitivities of neurons related to a visual reaction time task in the monkey prefrontal cortex. J Neurophysiol 1987; 58: 1100–1122.CrossRefGoogle ScholarPubMed
37.Rinne, JO, Rummukainen, J, Paljarvi, L, et al. Dementia in Parkinson’s disease is related to neuronal loss in the medial substantia nigra. Ann Neurol 1989; 26: 47–50.CrossRefGoogle ScholarPubMed
38.Lamarre, Y, Jacks, B. Involvement of the cerebellum in the initiation of fast ballistic arm movement in the monkey. Contemp Clin Neurophysiol 1978; 34 (2): 441–447 (EEG, Suppl.).Google Scholar
39.Spidalieri, G, Busby, L, Lamarre, Y. Fast ballistic arm movements triggered by visual, auditory and somesthetic stimuli in the monkey. II. Effects of unilateral dentate lesion on discharge of precentral cortical neurons and reaction time. J Neurophysiol 1983; 50: 1359–1379.CrossRefGoogle ScholarPubMed
40.Cox, JA, Lysko, PG, Henneberry, RC. Excitatory amino acid neurotoxicity at the N-methyl-D-aspartate receptor in cultured neurons: role of the voltage dependent magnesium block. Brain Res 1989; 499: 266–272.CrossRefGoogle ScholarPubMed
41.Henneberry, RC, Novelli, A, Cox, JA, et al. Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. Ann NY Acad Sci 1989; 558: 225–233.CrossRefGoogle Scholar
42.Bormann, J. Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur J Pharmacology 1989; 166: 591–592.CrossRefGoogle ScholarPubMed
43.Kornhuber, J, Bormann, J, Retz, W, et al. Memantine displaces (3H) MK-801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 1989; 166: 589–590.CrossRefGoogle ScholarPubMed